DDInter1042 DDInter1595
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior.
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Rilpivirine {u} (Compound) binds {v} (Gene) CYP3A4
Rilpivirine {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Reverse Transcriptase Inhibitors
Rilpivirine {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Rilpivirine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Rilpivirine {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Rilpivirine {u} may lead to a major life threatening interaction when taken with {v} Ranitidine
Rilpivirine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Rilpivirine (Compound) resembles Etravirine (Compound)
Rilpivirine (Compound) binds CYP3A4 (Gene)
Rilpivirine (Compound) is included by Non-Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Rilpivirine (Compound) causes Blood creatinine increased (Side Effect)
Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Rilpivirine may lead to a major life threatening interaction when taken with Lumacaftor
Rilpivirine may lead to a major life threatening interaction when taken with Ranitidine
Rilpivirine (Compound) resembles Pazopanib (Compound) and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib